Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (b-cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 1 stopped | 0.20 |
| literature PubMed | 3 Parkinson's papers of 2,909 | 0.82 |
| pathways Reactome | 2 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 14611
Sealed predictions
- CR2 in dopamine neurons, braak+0.85 (p 0.004) → +0.20 (p 0.597)receipt 14619
Swarm cases
receipt 14619: CR2 in dopamine neurons, braak
- power
- full sample +0.49 (p 0.040, n 18), 95% CI +0.03 to +0.78. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.53 (p 0.024, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.53 (p 0.024, n 18). not the mix.
- skeptic
- leave-one-out range +0.41 to +0.60, sign flips 0; without severely affected donors +0.49 (p 0.040, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CR2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts